<p>/PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (纳斯达克代码：ELOX)（&#34;Eloxx&#34;和&#34;公司&#34;），是一家临床阶段的生物制药公司，开发旨在调节核糖体并促进由于无义突变引起的早期终止密码子的读通过的创新小分子产品候选药物，以实现全长蛋白质的生产。今天宣布以每股 11.00 美元的公开发行价格，公开发行 2,975,000 股普通股，并以每个预先融资认购权证 10.99 美元的公开发行价格，发行最多 3,025,000 股普通股的预先融资认购权证，后者等于普通股每股的公开发行价格减去每个预先融资认购权证的 0.01 美元行使价格。所有将在此次发行中出售的证券均由 Eloxx 提供。Eloxx 预计在扣除承销折扣和佣金及 Eloxx 应支付的发行费用之前，将获得 6600 万美元的毛收益。普通股预计将于 2026 年 6 月 9 日在纳斯达克资本市场开始交易，交易代码为&#34;ELOX&#34;。此次发行预计将于 2026 年 6 月 10 日完成，前提是满足惯例的交割条件。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2996078/Eloxx_Pharmaceuticals_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2996078/Eloxx_Pharmaceuticals_Logo.jpg"/></p>
<p>Leerink Partners 和 Guggenheim Securities 担任此次发行的联合账簿管理人。LifeSci Capital 担任此次发行的被动账簿管理人。</p>
<p>与此次发行相关的 S-1 表格注册声明（文件编号：333-295651）已向证券交易委员会（&#34;SEC&#34;）提交，并于 2026 年 6 月 8 日生效。此次拟议的发行仅通过招股说明书进行。有关此次发行的最终招股说明书的副本可从以下地址获得：Leerink Partners LLC，承销部，53 State Street，40 楼，波士顿，MA 02109，或拨打电话（800）808-7525 分机 6105，或通过电子邮件联系 syndicate@leerink.com；以及 Guggenheim Securities, LLC，注意：股票承销部，330 Madison Avenue，纽约，NY 10017，电话（212）518-9544，或通过电子邮件联系 GSEquityProspectusDelivery@guggenheimpartners.com。</p>
<p>本新闻稿不构成出售要约或购买要约的征求，也不构成在任何州或司法管辖区内进行这些证券的销售，若在任何此类州或司法管辖区内的证券法下，进行此类要约、征求或销售将是非法的，除非已注册或获得资格。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据 1995 年《私人证券诉讼改革法》定义的前瞻性声明。除历史事实外，本新闻稿中包含的所有声明，包括但不限于关于预计发行收益、普通股在纳斯达克资本市场的预期交易日期以及预计发行完成时间的声明均为前瞻性声明。前瞻性声明可以通过&#34;目标&#34;、&#34;可能&#34;、&#34;将&#34;、&#34;会&#34;、&#34;应该&#34;、&#34;期望&#34;、&#34;探索&#34;、&#34;计划&#34;、&#34;预期&#34;、&#34;可以&#34;、&#34;打算&#34;、&#34;目标&#34;、&#34;项目&#34;、&#34;考虑&#34;、&#34;相信&#34;、&#34;估计&#34;、&#34;预测&#34;、&#34;潜在&#34;、&#34;寻求&#34;或&#34;继续&#34;等词语或这些词语的否定形式来识别，尽管并非所有前瞻性声明都包含这些词。前瞻性声明基于管理层当前的计划、估计、假设和基于公司当前可用信息的预测。前瞻性声明受到已知和未知的风险、不确定性和假设的影响，实际结果或结果可能因各种重要因素而与前瞻性声明中表达或暗示的结果有重大不同，包括但不限于市场条件和在公司于 2026 年 6 月 4 日提交的 S-1 表格注册声明中讨论的其他重要因素下的&#34;风险因素&#34;。</p>
<p>所有前瞻性声明仅在本新闻稿日期有效，除非适用法律要求，公司没有义务更新或修订本声明中包含的任何前瞻性声明，无论是由于新信息、未来事件、情况变化或其他原因。</p>
<p><strong>联系方式：</strong> Eloxx Pharmaceuticals 投资者关系</p>
<p>ir@eloxxpharma.com</p>
<p>(781) 577-5300</p>
<p>来源：Eloxx Pharmaceuticals, Inc.</p>

ELOX

<p>Eloxx Pharmaceuticals 宣布了一项 6600 万美元的公开发行定价，出售 2,975,000 股普通股，价格为 11.00 美元，并预售最多 3,025,000 股的预付认股权证，价格为 10.99 美元。公司预计在扣除费用前的毛收入为 6600 万美元。预计在 2026 年 6 月 9 日开始在纳斯达克交易，预计在 2026 年 6 月 10 日完成交易。Leerink Partners 和 Guggenheim Securities 是联合主承销商</p>

<p>, /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) (&#34;Eloxx&#34; and the &#34;Company&#34;), a clinical-stage biopharmaceutical company developing novel, small molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations to enable the production of full-length proteins, today announced the pricing of a public offering of 2,975,000 shares of common stock at a public offering price of $11.00 per share and, in lieu of shares of common stock, pre-funded warrants to purchase up to 3,025,000 shares of common stock at a public offering price of $10.99 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.01 per share exercise price of each pre-funded warrant. All of the securities to be sold in the offering are being offered by Eloxx. Eloxx expects to receive gross proceeds of $66.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Eloxx. The shares of common stock are expected to begin trading on the Nasdaq Capital Market on June 9, 2026, under the symbol &#34;ELOX&#34;. The offering is expected to close on June 10, 2026, subject to the satisfaction of customary closing conditions.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (纳斯达克代码：ELOX)（&#34;Eloxx&#34;和&#34;公司&#34;），是一家临床阶段的生物制药公司，开发旨在调节核糖体并促进由于无义突变引起的早期终止密码子的读通过的创新小分子产品候选药物，以实现全长蛋白质的生产。今天宣布以每股 11.00 美元的公开发行价格，公开发行 2,975,000 股普通股，并以每个预先融资认购权证 10.99 美元的公开发行价格，发行最多 3,025,000 股普通股的预先融资认购权证，后者等于普通股每股的公开发行价格减去每个预先融资认购权证的 0.01 美元行使价格。所有将在此次发行中出售的证券均由 Eloxx 提供。Eloxx 预计在扣除承销折扣和佣金及 Eloxx 应支付的发行费用之前，将获得 6600 万美元的毛收益。普通股预计将于 2026 年 6 月 9 日在纳斯达克资本市场开始交易，交易代码为&#34;ELOX&#34;。此次发行预计将于 2026 年 6 月 10 日完成，前提是满足惯例的交割条件。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2996078/Eloxx_Pharmaceuticals_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/2996078/Eloxx_Pharmaceuticals_Logo.jpg"/></p>
<p>Leerink Partners and Guggenheim Securities are acting as joint bookrunning managers for the offering. LifeSci Capital is acting as passive bookrunner for the offering.</p>
<div class="lb-trans"><p>Leerink Partners 和 Guggenheim Securities 担任此次发行的联合账簿管理人。LifeSci Capital 担任此次发行的被动账簿管理人。</p>
</div><p>A registration statement on Form S-1 (File No. 333-295651) relating to the offering has been filed with the Securities and Exchange Commission (the &#34;SEC&#34;) and became effective on June 8, 2026. The proposed offering is being made only by means of a prospectus. A copy of the final prospectus relating to the offering may be obtained from: Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.</p>
<div class="lb-trans"><p>与此次发行相关的 S-1 表格注册声明（文件编号：333-295651）已向证券交易委员会（&#34;SEC&#34;）提交，并于 2026 年 6 月 8 日生效。此次拟议的发行仅通过招股说明书进行。有关此次发行的最终招股说明书的副本可从以下地址获得：Leerink Partners LLC，承销部，53 State Street，40 楼，波士顿，MA 02109，或拨打电话（800）808-7525 分机 6105，或通过电子邮件联系 syndicate@leerink.com；以及 Guggenheim Securities, LLC，注意：股票承销部，330 Madison Avenue，纽约，NY 10017，电话（212）518-9544，或通过电子邮件联系 GSEquityProspectusDelivery@guggenheimpartners.com。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售要约或购买要约的征求，也不构成在任何州或司法管辖区内进行这些证券的销售，若在任何此类州或司法管辖区内的证券法下，进行此类要约、征求或销售将是非法的，除非已注册或获得资格。</p>
</div><p><strong>Forward-looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including without limitation, statements regarding the anticipated proceeds from the offering, the expected trading date for the shares of common stock on the Nasdaq Capital Market and the anticipated timing of closing of the offering are forward-looking statements. Forward-looking statements can be identified by the words &#34;aim,&#34; &#34;may,&#34; &#34;will,&#34; &#34;would,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;explore,&#34; &#34;plan,&#34; &#34;anticipate,&#34; &#34;could,&#34; &#34;intend,&#34; &#34;target,&#34; &#34;project,&#34; &#34;contemplate,&#34; &#34;believe,&#34; &#34;estimate,&#34; &#34;predict,&#34; &#34;potential,&#34; &#34;seeks,&#34; or &#34;continue&#34; or the negative of these terms similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on management's current plans, estimates, assumptions and projections based on information currently available to the Company. Forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and actual results or outcomes may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to market conditions and other important factors discussed under the caption &#34;Risk Factors&#34; in the Company's Registration Statement on Form S-1 filed on June 4, 2026.</p>
<div class="lb-trans"><p>本新闻稿包含根据 1995 年《私人证券诉讼改革法》定义的前瞻性声明。除历史事实外，本新闻稿中包含的所有声明，包括但不限于关于预计发行收益、普通股在纳斯达克资本市场的预期交易日期以及预计发行完成时间的声明均为前瞻性声明。前瞻性声明可以通过&#34;目标&#34;、&#34;可能&#34;、&#34;将&#34;、&#34;会&#34;、&#34;应该&#34;、&#34;期望&#34;、&#34;探索&#34;、&#34;计划&#34;、&#34;预期&#34;、&#34;可以&#34;、&#34;打算&#34;、&#34;目标&#34;、&#34;项目&#34;、&#34;考虑&#34;、&#34;相信&#34;、&#34;估计&#34;、&#34;预测&#34;、&#34;潜在&#34;、&#34;寻求&#34;或&#34;继续&#34;等词语或这些词语的否定形式来识别，尽管并非所有前瞻性声明都包含这些词。前瞻性声明基于管理层当前的计划、估计、假设和基于公司当前可用信息的预测。前瞻性声明受到已知和未知的风险、不确定性和假设的影响，实际结果或结果可能因各种重要因素而与前瞻性声明中表达或暗示的结果有重大不同，包括但不限于市场条件和在公司于 2026 年 6 月 4 日提交的 S-1 表格注册声明中讨论的其他重要因素下的&#34;风险因素&#34;。</p>
</div><p>All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, the Company has no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p>
<div class="lb-trans"><p>所有前瞻性声明仅在本新闻稿日期有效，除非适用法律要求，公司没有义务更新或修订本声明中包含的任何前瞻性声明，无论是由于新信息、未来事件、情况变化或其他原因。</p>
</div><p><strong>Contact:</strong> Eloxx Pharmaceuticals Investor Relations</p>
<div class="lb-trans"><p><strong>联系方式：</strong> Eloxx Pharmaceuticals 投资者关系</p>
</div><p>ir@eloxxpharma.com</p>
<div class="lb-trans"><p>ir@eloxxpharma.com</p>
</div><p>(781) 577-5300</p>
<div class="lb-trans"><p>(781) 577-5300</p>
</div><p>SOURCE Eloxx Pharmaceuticals, Inc.</p>
<div class="lb-trans"><p>来源：Eloxx Pharmaceuticals, Inc.</p>
</div>

Eloxx Pharmaceuticals, Inc. 宣布 6600 万美元公开发行的定价及在纳斯达克上市 | ELOX 股票新闻